Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors | Zendy

AI Assistant Blog Pricing

Open Access

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors

Author(s) -

Stuart J. Wong,

Karrison,

Hayes,

Kies,

Cullen,

Tanvetya,

Argiris,

Takebe,

WanTeck Lim,

Saba,

Worden,

Gilbert,

Lenz,

Razak,

Roberts,

Vokes,

Cohen

Publication year - 2016

Publication title -

carolina digital repository (university of north carolina at chapel hill)

Language(s) - English

DOI - 10.17615/kz22-gz40

Subject(s) - adenoid cystic carcinoma , dasatinib , medicine , salivary gland , pathology , oncology , carcinoma , cancer research , tyrosine kinase , receptor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.